肝細胞癌に対する経皮的マイクロ波凝固療法の治療成績

概要

論文の詳細を見る
JIS scores, an integrated staging system for hepatocellular carcinoma (HCC) that combines degree of tumor advancement and the reserve capability of the liver, and said to excel in stratifying patient prognoses. In this study, we used 867 HCC patients to compare, according to their JIS scores, the prognosis among patients given percutaneous microwave coagulation therapy (PMCT), hepatic resection, and percutaneous ethnaol injection therapy (PEIT). The results showed that, among subjects whose JIS score was 0 points, those who underwent PMCT (n = 28) had a 5-year survival rate of 85% ; the rate for those who underwent liver resection (n = 35) was 72% ; and the rate for those who underwent PEIT (n = 36) was 82%, showing no differences. However, the 5-year non-recurrence rate was 49% for the liver resection group, 39% for the PMCT group, and 7% for the PEIT group, showing better rates for the liver resection group (p < 0.01) and the PMCT group (p < 0.05) than the PEIT group. Based on the above, it was suggested that Stage I HCC patients were good candidates for PMCT.
特定非営利活動法人 Microwave Surgery研究会の論文